Radiopharm Theranostics Limited is classed by the SEC under Pharmaceutical Preparations (industry code 2834). In its latest annual figures on file, for the fiscal year ended 2025-06-30, it reported revenue of $4 million and a loss of $38 million (its filed statements).
Pre-revenue companyPharmaceutical Preparationsfilings since 20226 of 9 filed, 3 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.7 out of ten, 6 of 9 metrics filed and 3 estimated: past 7.9 out of ten, present 4.0 out of ten, future 5.8 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2022. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 9.4 out of ten. +252.2% a year over 3 filed years; profit years unseen. 94th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.8 out of ten. CrossAssetData estimate 5.8/10, confidence 20 of 100 (family median). 50th percentile among 295 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Financial health (present): 2.0 out of ten. Leverage 50%: owes 50¢ per asset dollar. 20th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 6.3 out of ten. top 37% of 314 in its family. 63rd percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 371 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 4.1 out of ten. bottom 41% of 272 in its family for room to expand. 41st percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 7.3 out of ten. top 27% of 307 in its family for growth drivers. 73rd percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 235 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 20-F filed 2026-09-30 for the period ended 2026-06-30 (on EDGAR). Newest filing: Form 6-K, 2026-10-05. Filings on record since 2022. Read from EDGAR 2026-10-12.
Who runs it
Canevari, Riccardo (Managing Director and CEO); Laurita, Aaron James (Chief Financial Officer); Voliotis, Dimitris (Chief Medical Officer); Hopper, Paul (director); Donnelly, Noel (director); Turner, Ian Lawrence (director); Larkin, Hester Denise (director); Goodwin, Bruce Michael (director). 8 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.